Analyst Expectations for ACADIA Pharmaceuticals's Future
Portfolio Pulse from Benzinga Insights
ACADIA Pharmaceuticals (NASDAQ:ACAD) has received various analyst ratings in the last quarter, with a total of 20 analysts giving an average price target of $28.43, which is lower than the current price of $29.2. This average price target has increased by 16.37% from the previous average of $24.43.
August 04, 2023 | 1:06 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
ACADIA Pharmaceuticals has received mixed analyst ratings, with an average price target lower than the current price, indicating a potential downside.
Analyst ratings are a significant factor in influencing stock prices. In the case of ACADIA Pharmaceuticals, the average price target given by analysts is lower than the current price, which suggests that the stock may experience a downside in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100